LNP characterization: Your guide to smarter analytics

Discover how to analyze lipid nanoparticles with confidence — from size and surface charge to thermal stability – with our eBook, Accelerating LNP Therapeutics.

In the race to develop next-generation RNA and gene therapies, lipid-based nanoparticles (LNPs) are leading the charge. But their structural complexity makes them notoriously difficult to characterize. This eBook is your essential guide to overcoming those challenges with the right analytical tools and strategies.

Whether you're optimizing formulations, scaling up production, or ensuring batch-to-batch consistency, this guide gives you the insights you need to make confident, data-driven decisions.

In the race to develop next-generation RNA and gene therapies, lipid-based nanoparticles (LNPs) are leading the charge. But their structural complexity makes them notoriously difficult to characterize. This eBook is your essential guide to overcoming those challenges with the right analytical tools and strategies.

Whether you're optimizing formulations, scaling up production, or ensuring batch-to-batch consistency, this guide gives you the insights you need to make confident, data-driven decisions.

In this eBook, you’ll discover how to:

  • Pinpoint critical LNP attributes — like size, polydispersity, concentration, and zeta potential — and why they matter.
  • Choose the right analytical tools for every stage of development, from early R&D to quality control.
  • Avoid common pitfalls in LNP characterization, including misleading results from traditional techniques.
  • Streamline your workflows with automation and orthogonal methods that save time and reduce sample waste.
  • Enhance thermal stability analysis to ensure your LNPs and RNA payloads stay structurally sound under stress.
  • Don’t let analytical blind spots slow you down. Get the clarity you need to develop safer, more effective LNP-based therapies — and bring them to patients faster.

Who should read this eBook

  • Scientists and project leaders working on the design, process and formulation development of lipid nanoparticles (LNPs) for drug and vaccine delivery. 

Please login or register for free now to download your copy.


Excerpts

“LNP vector size is a critical attribute for the function of LNP-based therapies, as it can determine tissue penetration (and, therefore, in vivo efficacy). In addition to giving you insight into LNP function, accurately measuring the size of your LNP vectors can also help you identify potential instability in your sample…”

“Similar to MADLS and DLS, NTA also uses very small sample volumes (1 μl, before dilution), non-destructively, and with little sample preparation needed.  However, NTA has a few downsides that you should be aware of….”

“The polydispersity index (PDI) is a useful and common parameter for measuring sample heterogeneity. It’s a dimensionless measure that describes the broadness of the sample size distribution, and ranges from 0.01 (perfectly uniform) to >1 (highly polydisperse).”

“Concentration is another important attribute to measure when characterizing and tracking LNP therapies. Though not as commonly used (the methodologies used to measure concentration are still considered immature relative to particle sizing techniques), exploring concentration during the design, formulation, and processing of your LNP therapy is highly beneficial, as it helps to monitor yield.” 

In the race to develop next-generation RNA and gene therapies, lipid-based nanoparticles (LNPs) are leading the charge. But their structural complexity makes them notoriously difficult to characterize. This eBook is your essential guide to overcoming those challenges with the right analytical tools and strategies.

Whether you're optimizing formulations, scaling up production, or ensuring batch-to-batch consistency, this guide gives you the insights you need to make confident, data-driven decisions.

In this eBook, you’ll discover how to:

  • Pinpoint critical LNP attributes — like size, polydispersity, concentration, and zeta potential — and why they matter.
  • Choose the right analytical tools for every stage of development, from early R&D to quality control.
  • Avoid common pitfalls in LNP characterization, including misleading results from traditional techniques.
  • Streamline your workflows with automation and orthogonal methods that save time and reduce sample waste.
  • Enhance thermal stability analysis to ensure your LNPs and RNA payloads stay structurally sound under stress.
  • Don’t let analytical blind spots slow you down. Get the clarity you need to develop safer, more effective LNP-based therapies — and bring them to patients faster.

Who should read this eBook

  • Scientists and project leaders working on the design, process and formulation development of lipid nanoparticles (LNPs) for drug and vaccine delivery. 

Excerpts

“LNP vector size is a critical attribute for the function of LNP-based therapies, as it can determine tissue penetration (and, therefore, in vivo efficacy). In addition to giving you insight into LNP function, accurately measuring the size of your LNP vectors can also help you identify potential instability in your sample…”

“Similar to MADLS and DLS, NTA also uses very small sample volumes (1 μl, before dilution), non-destructively, and with little sample preparation needed.  However, NTA has a few downsides that you should be aware of….”

“The polydispersity index (PDI) is a useful and common parameter for measuring sample heterogeneity. It’s a dimensionless measure that describes the broadness of the sample size distribution, and ranges from 0.01 (perfectly uniform) to >1 (highly polydisperse).”

“Concentration is another important attribute to measure when characterizing and tracking LNP therapies. Though not as commonly used (the methodologies used to measure concentration are still considered immature relative to particle sizing techniques), exploring concentration during the design, formulation, and processing of your LNP therapy is highly beneficial, as it helps to monitor yield.”